Optimizing Behavioral Healthcare Delivery Through Technology
- Conditions
- Anxiety DisordersMood Disorders
- Interventions
- Behavioral: Cognitive behavioral therapyBehavioral: Cognitive behavioral therapy with AI
- Registration Number
- NCT05745103
- Lead Sponsor
- Eleos Health
- Brief Summary
The goal of this randomized controlled clinical trial is to determine the feasibility, acceptability, and preliminary efficacy of an artificial intelligence platform )שׁ( for behavioral health in facilitating better clinical outcomes for adult patients receiving outpatient therapy.
The main question\[s\] it aims to answer are:
* whether an AI platform designed for behavioral healthcare would be feasible and acceptable to patients and therapists.
* whether the depression and anxiety outcomes of adults receiving outpatient cognitive-behavioral therapy (CBT) in a community-based clinic would be superior among patients whose therapists used an AI-based platform to support clinical decision making and administrative tasks compared to patients receiving treatment-as-usual (TAU).
Participants will receive CBT for depression or anxiety and complete standardized assessments. Participants will be followed for the first two months of therapy.
- Detailed Description
The need for scalable delivery of mental health care services that are efficient and effective is now a major public health priority. Artificial intelligence (AI) tools have the potential to improve behavioral healthcare services by helping clinicians collect objective data on patients' progress, streamline their workflow, and automate administrative tasks.
The goal of this study is to determine the feasibility, acceptability, and preliminary efficacy of an AI platform for behavioral health in facilitating better clinical outcomes for patients receiving outpatient therapy.
This open randomized clinical trial will compare an AI platform provided by Eleos Health to treatment-as-usual (TAU) during the first 2 months of therapy. The study will be conducted at a community-based clinic in the U.S. Participants will be adults referred for outpatient, individual cognitive behavioral therapy for a main diagnosis of a depressive or anxiety disorder. Patients will be randomized to receive either therapy provided with the support of an AI platform developed by Eleos Health or TAU at the same clinic.
Data analysis will be carried out based on intention-to-treat principle. The primary outcomes include the feasibility and acceptability of the AI platform. Secondary outcomes include changes in depression (Patient Health Questionnaire-9) and anxiety (Generalized Anxiety Disorder-7) scores as well as treatment attendance and satisfaction.
Findings of this study will inform the optimization of future trials and services offered to individuals seeking mental health support in the U.S.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 46
- Older than 18 years old.
- Presenting for an outpatient CBT for a depressive or anxiety disorder.
- Age <18.
- individuals who are medically unstable for outpatient treatment.
- a severe mental health condition that might interfere with treatment compliance (e.g., psychotic depression, psychosis, active substance dependence).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment as Usual Cognitive behavioral therapy Participants randomized to the control group will receive the routine services provided in the center. Therapists providing TAU will be permitted to use the strategies they deen would be most successful. The Eleos Health Platform Cognitive behavioral therapy with AI Therapists in the AI group will use the HIPAA-compliant, secure, password-protected Eleos Health platform. This AI tool was designed for behavioral health to support clinical decision-making and automation of administrative tasks. The platform captures the therapist and patient's utterances during a treatment session, analyzes the data, and offers feedback on the implementation of EBPs. The platform also incorporates a measurement-based care component, wherein standardized assessment scales completed by clients are immediately summarized and graphed for the therapist, who can use these data to inform therapy and share them with the patient. Insights and key indicators from the session data and MBC are summarized into a progress note draft which the therapist can then submit or edit as needed.
- Primary Outcome Measures
Name Time Method Patient Health Questionnaire-9 (PHQ-9) 2 months The PHQ-9 is intended as a tool to assist clinicians with identifying and diagnosing depression.
Generalized Anxiety Disorder-7 (GAD-7) 2 months The GAD-7 is intended as a tool to assist clinicians with identifying and diagnosing anxiety.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Ozark Center
🇺🇸Joplin, Missouri, United States